HIV prevention trial (HPTN 083) stopped early based on positive efficacy results

Study (n=4600 MSM/transgender women who have sex with men) showed long-acting injection of cabotegravir, an HIV integrase inhibitor, is non inferior to daily oral PrEP with emtricitabine/tenofovir disoproxil in preventing HIV acquisition (incidence HIV 0.38% v 1.21%,respectively)

PharmaTimes